Hyperthyroidism News and Research

RSS

Hyperthyroidism is a disorder that occurs when the thyroid gland makes more thyroid hormone than the body needs. It is sometimes called thyrotoxicosis, the technical term for too much thyroid hormone in the blood. About 1 percent of the U.S. population has hyperthyroidism. Women are much more likely to develop hyperthyroidism than men.

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

Bausch + Lomb agrees to commercialize Paragon BioTeck's phenylephrine in US

Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon's phenylephrine in the United States on an exclusive basis beginning this month.

20 Apr 2013

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

VIVUS, Inc. announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes, hypertension and dyslipidemia in obese or overweight patients.

25 Mar 2013

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Subclinical hyperthyroidism does not lead to cardiovascular and total mortality

Subclinical hyperthyroidism is not associated with overall or cardiovascular mortality, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

21 Sep 2012

Prevalence MRSA laryngitis may be underestimated

Methicillin-resistant Staphylococcus aureus laryngitis may be more common than previously suspected, a new case series suggests.

17 Sep 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Endocrine Society revises clinical practice guideline for management of thyroid dysfunction

The Endocrine Society has made revisions to its 2007 Clinical Practice Guideline (CPG) for management of thyroid disease during pregnancy and postpartum. The CPG provides recommendations for diagnosis and treatment of patients with thyroid-related medical issues just before and during pregnancy and in the postpartum interval.

12 Aug 2012

Researchers develop improved expert system for diagnosis of thyroid disease

Researchers in India have developed an improved expert system for the diagnosis of thyroid disease.

3 Aug 2012

Excess maternal iodine supplementation can lead to congenital hypothyroidism in infants

Congenital hypothyroidism is thyroid hormone deficiency at birth that, if left untreated, can lead to neurocognitive impairments in infants and children. Although the World Health Organization recommends 200-300 -g of iodine daily during pregnancy for normal fetal thyroid hormone production and neurocognitive development, the US Institute of Medicine considers 1,100 -g to be the safe upper limit for daily ingestion.

26 Jul 2012

Vivus receives FDA approval for Qsymia to manage chronic weight

The U.S. Food and Drug Administration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management.

18 Jul 2012

Overactive thyroid gland may increase risk of hospitalization for heart and blood-vessel disease

An overactive thyroid gland, or hyperthyroidism, may increase the risk of hospitalization for heart and blood-vessel disease even after surgery to remove the gland, according to a new study. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

Osteoporosis screening recommended for men at risk

Men at increased risk for osteoporosis should undergo bone mineral density testing with dual energy X-ray absorptiometry, concludes The Endocrine Society’s Clinical Practice Guideline “Osteoporosis in Men.”

20 Jun 2012

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Amgen today announced top-line results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis.

8 Jun 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Link between insomnia and severity of perceived tinnitus symptoms

For the more than 36 million people plagued by tinnitus, insomnia can have a negative effect on the condition, worsening the functional and emotional toll of chronic ringing, buzzing, hissing or clicking in the head and ears, according to a new study from Henry Ford Hospital in Detroit.

19 Apr 2012

FDA approves Boca Pharmacal's generic Tapazole Methimazole tablets ANDA

Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Methimazole Tablets USP, 5mg and 10mg, the generic version of King Pharmaceuticals' Tapazole® Methimazole tablets, indicated to treat hyperthyroidism.

10 Mar 2012

Exposure to iodinated contrast media may increase risk of hyperthyroidism

Exposure to iodinated contrast media during imaging procedures is associated with changes in thyroid function, and increased risk of developing hyperthyroidism, according to a report in the January 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

24 Jan 2012